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Abstract
Rationale—Ca2+/calmodulin-dependent protein kinase II (CaMKII) has been implicated as a 
maladaptive mediator of cardiac ischemic injury. We hypothesized that the inflammatory response 
associated with in vivo ischemia/reperfusion (I/R) is initiated through CaMKII signaling.
Objective—To assess the contribution of CaMKIIδ to the development of inflammation, infarct 
and ventricular dysfunction following in vivo I/R and define early cardiomyocyte-autonomous 
events regulated by CaMKIIδ using cardiac-specific knockout (KO) mice.
Methods and Results—Wild-type (WT) and CaMKIIδ KO mice were subjected to in vivo I/R 
by occlusion of the left anterior descending (LAD) artery for 1-hr followed by reperfusion for 
various times. CaMKIIδ deletion protected the heart against I/R damage as evidenced by 
decreased infarct size, attenuated apoptosis and improved functional recovery. CaMKIIδ deletion 
also attenuated I/R induced inflammation and upregulation of NF-κB target genes. Further studies 
demonstrated that I/R rapidly increases CaMKII activity, leading to NF-κB activation within 
minutes of reperfusion. Experiments using cyclosporine A and cardiac-specific CaMKIIδ 
knockout mice indicate that NF-κB activation is initiated independent of necrosis and within 
cardiomyocytes. Expression of activated CaMKII in cardiomyocytes lead to I kappa B kinase 
(IKK) phosphorylation and concomitant increases in nuclear p65. Experiments using an IKK 
inhibitor support the conclusion that this is a proximal site of CaMKII-mediated NF-κB activation.
Conclusions—This is the first study demonstrating that CaMKIIδ mediates NF-κB activation in 
cardiomyocytes following in vivo I/R and suggests that CaMKIIδ serves to trigger, as well as to 
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sustain subsequent changes in inflammatory gene expression that contribute to myocardial I/R 
damage.
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Ischemic heart disease; myocardial inflammation; reperfusion injury; nuclear factor kappa B; 
Ca2+/calmodulin-dependent protein kinase II
INTRODUCTION
Cardiac reperfusion following an acute myocardial infarction (MI) contributes to myocyte 
damage, generating what is referred to as myocardial ischemia/reperfusion (I/R) injury. 
Cardiomyocyte cell death in response to I/R results from increases in Ca2+ and reactive 
oxygen species (ROS) and is mediated through opening of the mitochondrial permeability 
transition (PT) pore1, 2. Subsequent to necrotic cardiomyocyte cell death, an inflammatory 
cascade which perpetuates further damage to cardiac tissue is activated3–5. One of the 
central players in inflammatory signaling is the transcription factor nuclear factor kappa B 
(NF-κB). Numerous reports have shown that NF-κB is activated following myocardial 
I/R6–9. Activated NF-κB translocates to the nucleus following release from its inhibitory 
subunit IκBα leading to transcriptional regulation of the expression of interleukins and 
cytokines. The NF-κB-mediated inflammatory cascade can be perpetuated through the 
ability of NF-κB targets such as TNFα and interleukins to further activate NF-κB signaling, 
as well as by the infiltration of neutrophils and other mononuclear inflammatory cells at 
sites of injury. The observation that cardiac specific overexpression of a dominant-negative 
IκBα10 or inhibition of IκBα degradation11 block NF-κB activation, reduce infarct size and 
preserve heart function in response to ischemia/reperfusion indicate that the activation of 
NF-κB within the cardiomyocyte is critical to this series of events. Pharmacological 
inhibitors of NF-κB activation also provide protection against cardiac I/R injury, attenuate 
the release of TNFα and IL-6, inhibit inflammation and apoptosis, reduce infarct size and 
improve functional recovery12–14. Thus inflammation mediated through NF-κB plays a 
critical role in infarct development following I/R.
While a maladaptive role of NF-κB in I/R injury is well documented, the initiating signals 
and cellular sites at which this response is triggered have not been fully elucidated. Ca2+/
calmodulin-dependent kinase II (CaMKII), a multifunctional heteromeric serine/threonine 
protein kinase, is activated by both Ca2+ and oxidative stress15. CaMKII has been 
demonstrated to mediate ex vivo I/R injury and cardiac remodeling after myocardial 
infarction based on experiments using pharmacological inhibitors or transgenic mice 
overexpressing a CaMKII inhibitory peptide16–19. CaM kinase has also been demonstrated 
to play a role in inflammatory gene expression in macrophages20–22. Our laboratory 
generated conventional knockout (KO) mice23 and more recently cardiac specific knockout 
mice (CKO) in which the predominant cardiac CaMKII isoform, CaMKII delta (δ)24–27 is 
deleted. The studies presented here use these CaMKIIδ KO mouse lines to test the 
hypothesis that CaMKII is required for the initiation of I/R induced NF-κB activation in 
cardiomyocytes and plays a critical role in the subsequent inflammatory responses that 
contribute to myocardial I/R damage.
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Please see detailed Methods in the Online Supplement which provide expanded details of in 
vivo I/R and hemodynamic measurements, heart tissue preparation and nuclear 
fractionation, TUNEL, DNA laddering, CaMKII and NF-κB activity assays, 
immunofluorescence staining and affymetrix gene array analysis. Generation of global 
CaMKIIδ KO mice was described previously23. Cardiac specific CaMKIIδ KO mice were 
generated by crossing heterozygous floxed CaMKIIδ mice23 with MLC 2v-Cre mice28 as 
detailed in the Online Supplement. Myocardial I/R was induced by left anterior descending 
(LAD) coronary artery occlusion for 1 hr followed by reperfusion for various times up to 24 
hrs. All animal studies were performed in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee of UCSD.
Statistical analysis
Data are presented as mean ± SEM as indicated and were analyzed by 2-tailed Student’s t 
test between 2 groups or by ANOVA when 3 or more groups were compared. P values of 
less than 0.05 were considered statistically significant.
RESULTS
Infarct size and heart function
To test the role of CaMKIIδ in myocardial tolerance to I/R injury, CaMKIIδ KO and WT 
mice were subjected to left anterior descending coronary artery ligation for 1 hr followed by 
reperfusion for various times. Using a direct kinase activity assay, we demonstrate that 
CaMKII is activated (Ca2+ independent “autonomous” activity is increased) in WT mice at 
3-min reperfusion following 1-hr in vivo ischemia (Figure 1A). As a further readout of 
CaMKII activation we measured phosphorylation of two substrates, the type two ryanodine 
receptor (RyR2) and phospholamban (PLN), at their CaMKII-specific phosphorylation sites. 
Marked time-dependent increases in RyR2 Ser2814 and PLN Thr17 phosphorylation were 
observed following reperfusion in WT but not in CaMKIIδ KO mice (Figure 1B).
Susceptibility to and recovery from I/R injury was then assessed. The area at risk (AAR) 
was not different in CaMKIIδ KO and WT littermates but infarct size following I/R was 
significantly reduced in the KO hearts (Figure 1C; infarct size/AAR: 46.5±7.5% in WT vs. 
32.8 ± 4.3% in KO, p<0.05). The decreased infarct was accompanied by improved 
functional recovery. Maximal left ventricular pressure (LVPmax), dP/dtmax and dP/dtmin 
were not different in WT or KO mice at baseline23 or under sham conditions (Online Table I 
and Figure 1 legend). Values for dP/dtmax and dP/dtmin measured at 24-hr reperfusion were, 
however, both significantly greater (p<0.05) in KO than in WT mice (Figure 1D). The 
difference in dP/dtmax was likely not due to altered preload since LVEDP was normal and 
did not differ between the two groups (Online Table I). The improved dP/dtmin observed 
following I/R in the KO mice may have reflected the higher LVPmax in this group since tau, 
a preferable measure of global LV relaxation, did not differ between WT and KO mice.
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It is well accepted that cardiomyocyte cell death contributes to I/R injury. We examined the 
extent of apoptosis at 24-hr reperfusion following 1-hr ischemia. Apoptosis assessed by 
TUNEL staining (Figure 2A), DNA laddering (Figure 2B) and the level of cleaved 
caspase-3 (Figure 2C) were significantly greater in WT than in KO mice. Inflammation, a 
recognized consequence of myocardial ischemic insult, was evidenced by enhanced 
mononuclear cell infiltration as assessed by CD68 staining. The increase in CD68 staining 
observed in WT hearts at 24-hr reperfusion was significantly diminished by CaMKIIδ 
deletion (Figure 2D). The expression of monocyte chemotactic protein-1 (MCP-1/CCR2) 
was also significantly increased in hearts of WT but not in KO mice following I/R (Figure 
2E).
NF-κB activation
The NF-κB family of transcription factors plays a central role in regulating the expression of 
inflammatory and cell death genes linked to cardiovascular pathology. We tested the 
hypothesis that NF-κB activation in response to I/R is regulated through CaMKIIδ. An early 
event in NF-κB activation is the degradation of IκBα. In WT mice, reperfusion following 1-
hr ischemia was accompanied by a rapid and transient decrease in IκBα expression; this 
response was seen as early as 5 minutes after reperfusion and prevented by CaMKIIδ 
deletion (Figure 3A). Subcellular fractionation of hearts isolated at various times after I/R 
demonstrated increases in the p65 NF-κB subunit in nuclear fractions from WT but not KO 
mice (Figure 3B). Finally we assessed NF-κB “activity” in ventricular lysates through 
binding to its consensus sequence (TransAM NF-κB oligonucleotide). NF-κB binding was 
not changed during ischemia, but quickly increased in WT hearts at 5 minutes and at 2 hrs of 
reperfusion; this increase was sustained throughout 24 hrs of reperfusion. (Figure 3C). In 
contrast, activation of NF-κB was not significantly increased in KO hearts at any time 
following reperfusion (Figure 3C).
To explore the dependence of NF-κB activation on opening of the mitochondrial PT pore 
and development of necrosis, mice were treated with cyclosporin A (CsA 10mg/kg, 
administrated intravenously 10 min before reperfusion). CsA treatment reduced cytochrome 
C release into cytosolic fractions following I/R, indicating effective PT pore inhibition 
(Figure 4A). Nuclear p65 translocation in response to I/R was, however, unchanged by CsA 
treatment (Figure 4B). This observation suggests that I/R can induce NF-κB activation 
independent of necrotic damage to mitochondria, consistent with the very rapid onset of NF-
κB activation.
Transcriptome analysis of I/R injury in WT and CaMKIIδ hearts
We used Affymetrix Gene arrays to compare changes in mRNA levels at 24-hrs reperfusion 
following 1-hr ischemia in WT and KO mouse hearts. There were 3129 differentially 
expressed transcripts in WT versus CaMKIIδ KO after I/R (interaction P<0.05 and 
minimum fold between groups > 20%) as shown in Figure 5A. The 5kb promoters of these 
differentially expressed genes were scanned for enrichment of evolutionarily conserved 
(human to mouse) transcription factor binding sites using the Whole Genome RVista tool29. 
Transcription factor binding sites enriched in the differentially regulated genes included 
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those for the known CaMKIIδ target MEF2c (−log10, P=12.3)30 and those for NF-κB 
(−log10 P=10.3). There were 313 predicted NF-κB target genes upregulated in WT hearts 
which were significantly suppressed or downregulated in CaMKIIδ KO hearts (Online Table 
II). Many of these genes clustered by Gene Ontology (GO) analysis into categories related to 
apoptosis, cytokine signaling and regulation of NF-κB signaling. A diagrammatic 
representation including some of the I/R regulated, CaMKII dependent NF-κB target genes 
is shown in Figure 5B.
CaMKII signaling to NF-κB
To directly demonstrate and determine the mechanism for CaMKII effects on NF-κB 
activation we expressed constitutively active CaMKIIδ in neonatal rat cardiomyocytes. The 
amount of nuclear p65 was increased in cells expressing CaMKIIδ (Figure 6A). In addition 
we determined that I kappa B kinase (IKK), a proximal kinase in the NF-κB signaling 
cascade, was phosphorylated when CaMKII activity was increased (Figure 6B). 
Pharmacological inhibiton of IKK with BMS-345541 blocked the ability of CaMKII to 
increase nuclear p65 (Figure 6A). These data suggest that CaMKII activates IKK to initiate 
NF-κB signaling. To test the importance of IKK activation and NF-κB signaling using the in 
vivo I/R injury model, BMS-345541 was administrated to mice intravenously at 2mg/kg 10 
min before reperfusion. The efficacy of IKK inhibition was evidenced by the ability of this 
drug to significantly decrease I/R induced NF-κB activation in WT mice (Figure 6C, third 
vs. fourth bars). Treatment of WT mice with BMS-345541 lead to a 31% decrease in infarct 
size (Figure 6D). In contrast the inhibitor did not further reduce I/R induced NF-κB 
activation or infarct size in KO mice (Figure 6C,D). The lack of additive protection by 
CaMKIIδ deletion plus NF-κB inhibition is consistent with there being a common 
mechanism underlying the benefit of deleting CaMKIIδ and of inhibiting NF-κB signaling. 
The finding that there is no additional benefit to CaMKII deletion when IKK is inhibited 
supports the cell based studies showing that CaMKII regulates NF-κB signaling in 
cardiomyocytes through IKK, rather than by regulating a more distal process in the NF-κB 
activation cascade.
Cardiac specific CaMKIIδ deletion and NF-κB signaling
The rapid activation of CaMKII and NF-κB suggests that this pathway is directly regulated 
by increases in Ca2+ and ROS signaling in cardiomyocytes. Nonetheless, it is possible that 
CaMKII regulates NF-κB signaling in inflammatory cells that are activated in or recruited to 
the heart during reperfusion. To directly demonstrate that the I/R protection afforded by 
CaMKIIδ deletion results from effects in the cardiomyocyte compartment we used cardiac 
specific CaMKIIδ KO (CKO) mice generated by crossing CaMKIIδfl/fl with MLC2v-Cre 
mice28. Consistent with our reported findings using global KO hearts23, and indicative of 
selective loss of CaMKII activity in the CKO mice, the basal phosphorylation of RyR2 and 
PLN at their CaMKII, but not at their PKA, phosphorylation sites was significantly reduced 
(Online Figure IIA). Cardiac specific deletion of CaMKIIδ did not, however, alter 
ventricular chamber dimension, wall thickness or cardiac function as assessed by 
echocardiography in mice at 2 months of age (Online Figure IIB). Cardiac specific CaMKIIδ 
KO mice subject to in vivo I/R were protected to an extent similar to that observed in the 
global CaMKIIδ KO mice. Infarct size/AAR was reduced to 31.7±1.6% in CKO vs. 
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43.7±4.2% in Ctrl (fl/fl) mice (Figure 7A). The degradation of IκBα and activation of NF-
κB observed at early times (5 to 30 min) after reperfusion was also significantly inhibited by 
cardiac specific CaMKIIδ deletion (Figure 7 B–C). In addition, the subsequent development 
of inflammation, assessed by CD68 staining at 24-hrs, was markedly attenuated in the 
cardiac specific CaMKIIδ KO mouse hearts (Figure 7D). Thus CaMKII signaling within the 
cardiomyocyte compartment initiates NF-κB activation and thereby contributes to I/R 
induced inflammation and infarct development.
DISCUSSION
The role of CaMKII in ischemic heart diseases
The current study provides evidence that CaMKIIδ is a mediator of the effects of I/R on 
IκBα degradation, NF-κB activation and upregulaton of putative NF-κB target genes and 
that its actions are mediated through IKK phosphorylation. This is the first report to utilize 
the cardiac specific CaMKIIδ KO mice generated in our laboratory. Studies using these mice 
provide evidence that deletion of CaMKIIδ within the cardiomyocyte results in no overt 
basal phenotype but markedly limits the ability of I/R to increase NF-κB activation. 
Concomitantly, CaMKIIδ gene deletion attenuates I/R induced cardiac inflammation, 
cardiomyocyte death, infarct development and loss of contractile function.
A series of studies from the Mattiazi group used the ex vivo isolated perfused heart to 
examine the involvement of CaMKII in global I/R injury16, 17. These studies concluded that 
the salutary effects of CaMKII inhibition result from preventing the disordered 
cardiomyocyte Ca2+ homeostasis that contributes to cell death and mechanical dysfunction 
following I/R. A primary target of CaMKII action was suggested by these studies to be the 
phosphorylation of phospholamban (PLN). We demonstrate that in vivo I/R increases 
phosphorylation of PLN and ryanodine receptor (RyR2) at CaMKII sites in WT but not in 
CaMKIIδ KO mice (Figure 1B). Thus I/R induced activation of CaMKII and 
phosphorylation of cytosolic Ca2+ handling proteins could contribute to mitochondrial 
dysfunction and subsequent necrotic cell death. Importantly, however, our data demonstrate 
that there is also a rapid CaMKII-mediated activation of NF-κB which is not secondary to 
necrosis and, while it may initially be protective31, sets into motion a subsequent series of 
proinflammatory processes. Furthermore whereas the ex vivo model used in the studies cited 
above can only assess short term responses, in vivo I/R brings into play a more 
physiologically complex and prolonged sequence of events. Reperfusion following ischemia 
in vivo is associated with influx of leukocytes and activation of endogenous inflammatory 
cells that contribute to development of apoptosis and cardiac inflammation. The studies 
presented here indicate that averting the early and proximal cardiomyocyte autonomous 
activation of NF-κB by CaMKIIδ deletion also significantly attenuates these more chronic 
inflammatory responses as well as the ventricular dysfunction observed 24 hrs after 
reperfusion.
In studies exploring the role of CaMKII in myocardial infarction, Singh et al linked CaMKII 
to inflammation, specifically focusing on complement factor B (CFB) gene expression and 
the deleterious effects of LPS and TNFα19. CaMKII activation was shown to be required for 
CFB expression in response to LPS and TNFα in isolated cardiomyocytes. Further studies 
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demonstrated that LPS-mediated activation of toll-like receptors, which contributes to 
cardiac NF-κB activation5, 32, 33, leads to CaMKII oxidation and activation in response to 
myocardial infarction34. The notion that increases in TLR and MyD88 activation lead to 
sustained CaMKII oxidation, contributing to NF-κB-mediated inflammatory gene 
expression following myocardial infarction, is wholly compatible with our data showing 
CaMKII-mediated increases in proinflammatory gene expression following in vivo I/R. 
What is most compelling, however, is that our studies also suggest that CaMKII is an 
initiator of inflammation through its direct role in NF-κB activation in the cardiomyocyte. 
Thus CaMKII serves as a trigger as well as an intermediate player in a sustained myocardial 
inflammatory cycle.
The role of CaMKII in NF-κB activation
As indicated in the introduction, NF-κB has been extensively implicated in myocardial I/R 
injury. There is abundant evidence that blocking NF-κB signaling limits infarct size, reduces 
neutrophil invasion and decreases inflammatory gene expression10–14, 35. Activation of NF-
κB proceeds through a number of distinct pathways that converge on the phosphorylation 
and subsequent proteasomal degradation of the IκB inhibitor protein. Degradation of this 
protein facilitates the translocation of NF-κB dimers to the nucleus where they bind target 
genes and activate transcription. In our studies comparing WT and CaMKIIδ KO mice we 
report, consistent with published studies12, that I/R leads to a rapid decrease in IκBα levels 
in WT mice. We demonstrate that IκBα degradation is attenuated by CaMKIIδ deletion 
suggesting that CaMKII either affects steps upstream of its phosphorylation or alters its 
proteasomal processing. We further show that both NF-κB nuclear translocation and it 
transcriptional activity are regulated through CaMKIIδ following I/R.
Our studies using BMS-345541, an inhibitor of IKK, the kinase responsible for IkB 
phosphorylation and its subsequent degradation, confirm the important role of NF-κB 
activation in infarct development following I/R. The data showing that pharmacological 
blockade of IκB kinase has no additional ameliorative effect when CaMKIIδ is deleted 
further imply that a common mechanism underlies the beneficial effects of blocking 
CaMKII and NF-κB signaling and suggests that NF-κB activation is directly downstream of 
CaMKII. Previous studies using neonatal rat cardiomyocytes and macrophages provided 
evidence that CaMKII can regulate NF-κB signaling19, 36, 37. Specifically, in neonatal rat 
cardiomyocytes CaMKIIδ overexpression was shown to increase IκBα degradation and NF-
κB-dependent promoter/luciferase activity36. We show here that a more proximal event, the 
activation of IKK, is regulated through CaMKIIδ in these cells. Whether IKK is a direct 
target of CaMKII-mediated phosphorylation remains to be determined. Nonetheless the 
finding that inhibiting IKK blocks the ability of CaMKII to elicit NF-κB activation in 
NRVMs and prevents further effects of CaMKII deletion on infarct development in the in 
vivo I/R model support the conclusion that IKK is the proximal site of CaMKII action.
NF-κB targets in CaMKII mediated I/R injury
We identified a significant number of genes with NF-κB binding sites in their 5’ upstream 
promoters that are upregulated by I/R in WT but not in CaMKIIδ KO mice. Which of these 
genes contribute to I/R-induced and CaMKII-mediated cardiomyocyte cell death, infarct 
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development and inflammation is not yet known. Anderson’s group focused on complement 
factor B (CFB) as a gene that responds to lipopolysaccharides (LPS) in a CaMKII dependent 
manner both in vitro and in vivo19. This is, however, only one of many genes detected in 
their gene arrays as CaMKII dependent19 and only one of the many genes identified in our 
arrays as being both CaMKII dependent and potentially NF-κB regulated. We specifically 
examined changes in the NF-κB regulated chemokine MCP-1 as a marker of inflammation, 
and demonstrated that the increases in MCP-1 protein expression seen 24 hrs after I/R are 
prevented by CaMKII deletion. Interestingly MCP-1 not only participates in chemoattraction 
but also regulates cell death pathways38, thus MCP-1 is a potential mediator through which 
NF-κB signals contribute to cardiomyocyte death and infarct expansion. Undoubtedly a 
multitude of proinflammatory gene products conspire to induce cardiomyocyte injury and 
contractile dysfunction following I/R. The profound ameliorative effect of CaMKIIδ 
deletion on the expression of myriad NF-κB target genes categorized as regulators of 
cytokine signaling and apoptosis implicates CaMKII as a nodal regulator of this process.
In summary, we demonstrate for the first time that CaMKIIδ mediates rapid NF-κB 
activation and the development of apoptosis and inflammation in response to I/R in the in 
vivo mouse heart. Our studies using cardiac specific CaMKIIδ KO mice reveal that the 
maladaptive effects of CaMKII signaling elicited by I/R are early events that occur in the 
cardiomyocyte compartment. The activation of NF-κB signaling is independent of necrosis 
and results in regulation of multiple NF-κB target genes. We suggest that oxidative stress or 
Ca2+ release during reperfusion initiate rapid CaMKIIδ activation which leads to 
cardiomyocyte autonomous IKK phosphorylation and NF-κB activation. The ensuing 
changes in cardiac gene expression and recruitment of infiltrating and resident inflammatory 
cells fuel the subsequent inflammatory cascade that contributes to further cardiomyocyte 
injury. Inhibiting CaMKII during reperfusion could provide significant therapeutic 
advantage by targeting an early causal event in this cascade.
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Nonstandard Abbreviations
I/R ischemia/reperfusion
CaMKII Ca2+/calmodulin-dependent kinase II
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CKO cardiac specific knockout
NF-κB nuclear factor kappa B
TNFα tumor necrosis factor alpha
IL- 6 Interleukin-6
LAD left anterior descending
IS infarction size
AAR area at risk
LV left ventricle
CsA cyclosporin A
IKK I kappa B kinase
RyR2 type 2 ryanodine receptor
PLN phospholamban
PT pore mitochondrial permeability transition pore
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• Calcium/calmodulin dependent kinase (CaMKII) is activated by calcium and 
reactive oxygen species (ROS).
• Reperfusion of the ischemic heart is associated with increased myocardial 
calcium and ROS generation, which lead to cardiac dysfunction.
• NF-κB, a master regulator of inflammation, contributes to tissue injury induced 
by cardiac ischemia/ reperfusion (I/R.)
What New Information Does This Article Contribute?
• CaMKII is activated within minutes of reperfusion and is required for NF-κB 
activation following in vivo I/R.
• CaMKII activates NF-κB directly by phosphorylating its upstream kinase - IKK.
• Activation of NF-κB by CaMKII is an early, cardiomyoctyte autonomous 
response that is critical for long- term inflammation, myocardial tissue injury 
and contractile dysfunction.
The mechanisms responsible for NF-κB activation in response to cardiac ischemia/
reperfusion are unknown. I/R associated increases in Ca2+ or ROS should activate 
CaMKII, but direct evidence is lacking. We found that CaMKII activity is rapidly 
increased in response to reperfusion and that CaMKII is required for subsequent 
activation of NF-κB. We demonstrate that these responses occur in a cardiomyocyte in a 
necrosis-independent manner and that CaMKII increases NF-κB activity through 
phosphorylation of its upstream kinase IKK. Deletion of CaMKII in cardiomyocytes 
prevents I/R mediated increases in NF-κB target gene expression, leads to a decrease in 
infarct size, and improved ventricular function at 24 h after I/R. These findings suggest 
that CaMKII-mediated NF-κB activation is an initiating signal that occurs in 
cardiomyocytes and is responsible for subsequent I/R injury. Blocking CaMKII could 
ameliorate excessive NF-κB mediated responses associated with various inflammatory 
diseases and in particular prove to be a viable therapeutic target for preventing the 
deleterious effects of myocardial reperfusion.
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Figure 1. CaMKII is activated by in vivo myocardial ischemia/reperfusion and CaMKIIδ 
deletion reduces infarct size and enhances functional recovery
Animals were subjected to 1-hr ischemia followed by various times of reperfusion. (A) 
Increases in autonomous CaMKII activity were measured at 3-min reperfusion. Data are 
mean ± SEM of values from 3 mice. *p<0.05 versus Sham. (B) Phosphorylation of RyR2 
and PLN at the CaMKII site was assessed in WT and CaMKIIδ KO mice at various times of 
reperfusion. Data are mean ± SEM of values from 3 determinations. *p<0.05 vs WT Sham. 
(C) Area at risk (AAR) and the ratio of infarct size to AAR were determined in WT and KO 
mice at 24-hr reperfusion. Data are mean ± SEM of values from 6 mice. (D) The maximum 
rates of rise and decline of left ventricular pressure (dP/dtmax and dP/dtmin) assessed at 24-
hr reperfusion. Data are mean ± SEM of values from 8 mice. *p<0.05 versus WT. The dP/
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dtmax and dP/dtmin values in sham-operated mice (~8500 and ~−6500 mmHg/sec 
respectively) were not significantly different for WT and KO.
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Figure 2. CaMKIIδ deletion reduces apoptosis and inflammation following in vivo ischemia/
reperfusion
Endpoints indicative of apoptosis and inflammation were assessed at 24-hr reperfusion 
following 1-hr ischemia. (A) TUNEL staining; apoptotic nuclei were stained (green) and 
cardiomyocytes were detected by wheat germ agglutinin staining (red). Original 
magnification is 20×. Data are mean ± SEM of values from 3 hearts per group, with at least 
5,000 nuclei examined per heart. *P < 0.05 versus WT I/R. (B) DNA laddering. (C) Cleaved 
caspase-3 as detected by Western blotting. Data are mean ± SEM of values from 3–4 
determinations. *p<0.05 vs Sham; #p<0.05 vs WT I/R. (D) Inflammatory cells were 
identified by CD68 staining. Original magnification is 20×. (E) MCP-1 expression levels 
measured by Western blotting. Data are mean ± SEM of values from 3–4 determinations. 
*p<0.05 vs Sham; #p<0.05 vs WT.
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Figure 3. CaMKIIδ deletion inhibits IκBα degradation, NF-κB nuclear localization and NF-κB 
activity in response to in vivo I/R
Animals were subjected to 1-hr ischemia followed by various times of reperfusion. (A) 
Degradation of IκBα was detected by Western blotting in hearts exposed to in vivo ischemia 
followed by various times of reperfusion. Data are mean ± SEM of values from 3–6 
determinations. *p<0.05 vs Sham; #p<0.05 vs WT I/R. (B) Translocation of NF-κB p65 to 
the nucleus was detected by Western blotting following nuclear fractionation. Lamin A/C 
was used as a loading control. Data are mean ± SEM of values from 3–6 determinations. 
*p<0.05 vs Sham; #p<0.05 vs WT I/R. (C) NF-κB activity was measured by the TransAM 
oligonucleotide binding assay. Data are mean ± SEM of values from 3–6 samples. *p<0.05 
vs Sham; #p<0.05 vs WT I/R.
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Figure 4. Inhibition of necrosis by CsA does not reduce NF-κB activation in response to in vivo 
I/R
Hearts were collected from mice treated ±CsA at 15-min reperfusion following 1-hr 
ischemia (A) Cytochrome C expression detected by Western blotting in mouse heart 
cytosolic fractions. GAPDH and VDAC were used as cytosolic and mitochondrial loading 
controls to assess purity of cytosolic fractions. Data are mean ± SEM of values from 3–4 
determinations. #p<0.05 vs I/R (B) Translocation of NF-κB p65 to the nucleus was detected 
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by Western blotting in nuclear fractions from the same hearts. Lamin A/C was used as a 
loading control. Data are mean ± SEM of values from 3–4 mice. *p<0.05 versus Sham.
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Figure 5. Clustering and functional annotation of transcripts differentially regulated by I/R in 
WT and CaMKIIδ hearts
(A) We identified 3129 transcripts that had a significant interaction (P<0.05) by genotype 
and I/R and clustered them with the HOPACH algorithm to identify major patterns of 
regulation. Rows represent probesets, columns are arrays; red indicates increase in 
expression and green indicates decreases in expression compared to baseline (sham) for each 
genotype (B) Network representation of selected gene ontology processes for the NF-κB 
target genes that are upregulated by I/R in WT versus CaMKIIδ KO hearts (i.e. putative NF-
κB target genes from clusters 2, 3 and 9). Grey nodes represent gene ontology terms. Red 
and green nodes respectively represent genes upregulated and downregulated by I/R, with 
intensity correlated with the magnitude of the response. The central core color shows fold 
changes in WT hearts and the surrounding ring shows fold changes in CaMKIIδ KO hearts.
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Figure 6. CaMKII induces I kappa B kinase (IKK) phosphorylation and inhibition of IKK 
reduces NF-κB activation and infarct development in response to in vivo I/R
For A and B, neonatal rat ventricular myocytes (NRVMs) were infected with adenovirus 
expressing GFP or constitutively active CaMKIIδ at 40 M.O.I. and harvested 24-hr after 
infection. (A) Translocation of NF-κB to the nucleus was detected by Western blotting 
following nuclear fractionation of cells treated ±15µM BMS-345541. Lamin A/C was used 
as a loading control. Data are mean ± SEM of values from 3 samples. *p<0.05 versus 
AdCMV; #p<0.05 vs CaMKIIδ. (B) Phosphorylated IKK was detected by Western blot. 
Data are mean ± SEM of values from 3 samples. *p<0.05 versus AdCMV. For C and D, 
hearts were collected at 24-hr reperfusion following 1-hr ischemia. (C) NF-κB activation by 
in vivo I/R measured by the TransAM oligonucleotide binding assay in WT and KO mice 
pretreated for 10 min with 2mg/kg BMS-345541 or vehicle. Data are mean ± SEM of values 
from 3 mice. *p<0.05 vs WT without BMS treatment. (D) Area at risk (AAR) and Infarct 
size to AAR ratio (IS/AAR) following in vivo I/R ±BMS treatment. Data are mean ± SEM 
of values from 4–6 determinations. *p<0.05 vs WT without BMS treatment.
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Figure 7. Cardiac specific deletion of CaMKIIδ protects against in vivo I/R injury
Animals were subjected to 1-hr ischemia followed by 24-hr reperfusion. (A) Area at risk 
(AAR) and Infarct size to AAR ratio (IS/AAR) in control and CKO hearts following I/R. 
Data are mean ± SEM of values from 4–5 determinations. *p<0.05 vs Ctrl I/R. (B) 
Degradation of IκBα detected by Western Blotting in control and CKO mouse hearts 
following I/R. Data are mean ± SEM of values from 3 determinations. *p<0.05 vs control 
Sham; #p<0.05 vs CKO Sham. (C) NF-κB activity was determined at the end of 1hr 
ischemia and after various times of reperfusion in control and KO hearts by TransAM 
oligonucleotide binding assay. Data are mean ± SEM of values from 3–4 determinations. 
*p<0.05 vs Sham; #p<0.05 vs Ctrl I/R. (D) CaMKIIδ deletion reduces inflammation 
following I/R. Inflammatory cells were identified by CD68 staining. Original magnification 
is 20×.
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